Martini DJ, Kline MR, Liu Y, et al. - By performing this retrospective study, researchers examined the link between types of fat and survival in patients who received immunotherapy. Participants included 90 patients managed with immunotherapy on phase 1 clinical trials at the Winship Cancer Institute in Atlanta, Georgia, from 2009 through 2017. Clinical results were measured by using overall survival (OS) and progression-free survival (PFS). Most of the participants were male (59%) and had received a diagnosis of melanoma (33%) or gastrointestinal cancers (22%). A significantly longer OS and PFS was observed among low-risk patients (those with a subcutaneous fat index [SFI] ≥ 73) vs those at intermediate risk (those with an SFI < 73 and intermuscular fat index [IFI] < 3.4) and poor risk (those with an SFI < 73 and IFI ≥ 3.4). The possible link of elevated BMI, increased SFI, and reduced IFI, with prolonged survival, was suggested among cancer patients who were treated with immunotherapy.